Treatment of hot flushes in breast and prostate cancer

Bibliography

• MCKINLAY SM, JEFFERYS M: The menopausal syndrome. Br. J. Prey. Soc. Med. (1974) 28(2):108–115.
   PubMedGoogle Scholar
• SPETZ AC, HAMMAR M, PETTERSSON W, VARENHORST E: Hot flushes and prostate cancer: pathogenesis and treatment. BJU Int. (2002) 90(4):476.
   PubMedGoogle Scholar
• CASPER RF, YEN SS: Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism. Clin. Endocrinol (1985) 22(3):293–312.
   PubMedGoogle Scholar
• KRONENBERG F: Hot flashes: phenomenology, quality of life, and search for treatment options. Exp. GerontoL (1994) 29(3-4):319–336.
   PubMed Web of Science ®Google Scholar
• ROBERTS J, CHAMBERS LF, BLAKE J, WEBBER C:Psychosocial adjustment in post-menopausal women. Can. j Nurs. Res. (1992) 24(4):29–46.
   PubMedGoogle Scholar
• FINCK G, BARTON DL, LOPRINZI CL, QUELLA SK, SLOAN JA: Definitions of hot flashes in breast cancer survivors./ Pain Symptom Manage. (1998) 16(5):327–333.
   PubMedGoogle Scholar
• STEIN KD, JACOBSEN PB, HANN DM, GREENBERG H, LYMAN G: Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer. J. Pain Symptom Manage. (2000) 19(6):436–445.
   PubMedGoogle Scholar
• DALY E, GRAY A, BARLOW D, MCPHERSON K, ROCHE M, VESSEY M: Measuring the impact of menopausal symptoms on quality of life. Br. Med. J. (1993) 307(6908):836–840.
   PubMed Web of Science ®Google Scholar
• CARPENTER JS, ANDRYKOWSKI Mk Menopausal symptoms in breast cancer survivors. Oncol. Nurs. Forum (1999) 26(8):1311–1317.
   PubMedGoogle Scholar
• ERLIKY, TATARYN IV MELDRUM DR, LOMAX P, BAJOREK JG, JUDD HL: Association of waking episodes with menopausal hot flushes. JAMA (1981) 245(17):1741–1744.
   PubMedGoogle Scholar
• BERG G, GOTTWALL T, HAMMAR M, LINDGREN R: Climacteric symptoms among women aged 60–62 in Linkoping, Sweden, in (1986) Maturitas (1988) 10(3):193–199.
   Google Scholar
• CARPENTER JS, ANDRYKOWSKI MA, CORDOVA M et al.: Hot flashes in postmenopausal women treated for breast carcinoma: prevalence, severity, correlates, management, and relation to quality of life. Cancer (1998) 82(9):1682–1691.
   PubMed Web of Science ®Google Scholar
• CHARIG, CR, RUNDLE JS: flashing. Long-term side effect of orchiectomy in treatment of prostatic carcinoma. Urology (1989) 33(3):175–178.
   Google Scholar
• SCHOW DA, RENFER LG, ROZANSKI TA, THOMPSON IM: Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South. Med. J. (1998) 91(9):855–857.
   PubMedGoogle Scholar
• KARLING P, HAMMAR M, VARENHORST E: Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J. Urol (1994) 152(4):1170–1173.
   PubMedGoogle Scholar
• HOLMBERG L, ANDERSON H: HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped. Lancet (2004) 363(9407):453–455.
   PubMed Web of Science ®Google Scholar
• WEISS LK, BURKMAN RT, CUSHING-HAUGEN KL et aL: Hormone replacement therapy regimens and breast cancer risk(1). Obstet. Gynecol (2002) 100(6):1148–1158.
   PubMed Web of Science ®Google Scholar
• ROSSOUW JE, ANDERSON GL, PRENTICE RL et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. /AMA (2002) 288(3):321–333.
   PubMed Web of Science ®Google Scholar
• BINES J, OLESKE DM, COBLEIGH Mk Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. Clin. Oncol. (1996) 14(5):1718–1729.
   Google Scholar
• STAROPOLI CA, FLAWS JA, BUSH TL, MOULTON AW: Predictors of menopausal hot flashes. J. Womens Health (1998) 7(9):1149–1155.
   PubMed Web of Science ®Google Scholar
• LOVE RR, CAMERON L, CONNELL BL, LEVENTHAL H: Symptoms associated with tamoxifen treatment in postmenopausal women. Arch. Intern. Med. (1991) 151(9):1842–1847.
   PubMed Web of Science ®Google Scholar
• LOPRINZI CL, ZAHASKY KM, SLOAN JA, NOVOTNY PJ, QUELLA SK: Tamoxifen-induced hot flashes. Clin Breast Cancer (2000) 1(1):52–56.
   PubMedGoogle Scholar
• BAUM M, BUZDAR A, CUZICK J et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer (2003) 98(9):1802–1810.
   PubMed Web of Science ®Google Scholar
• GOSS PE, INGLE JN, MARTINO Set al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl. J. Med. (2003) 349(19):1793–1802.
   PubMed Web of Science ®Google Scholar
• LONNING PE: Exemestane: a review of its clinical efficacy and safety. Breast (2001) 10(3):198–208.
   PubMedGoogle Scholar
• MORALES L, NEVEN P, TIMMERMAN D et al.: Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs (2004) 15(8):753–760.
   PubMed Web of Science ®Google Scholar
• HUGGINS C, SW, HODGES CV: Studies on Prostate Cancer III. The Effects of Fever of Desoxycorticosterone and of Estrogen on Clinical Patients with Metastatic Carcinoma of the Prostate. J. Urol. (1941) 46:997.
   Google Scholar
• HUGGINS C, HC: Studies on Prostate Cancer I. The Effects of Castration of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate. Cancer Res. (1941) 1:293.
   Google Scholar
• HUGGINS C, SR, HODGES CV: Studies on Prostate Cancer II. The Effects of Castration on Advanced Carcinoma of the Prostate Gland. Arch. Surg-. (1941) 43:209.
   Google Scholar
• FREEDMAN RR, KRELL W: Reduced thermoregulatory null zone in postmenopausal women with hot flashes. Am. J. Obstet. GynecoL (1999) 181(1):66–70.
   PubMed Web of Science ®Google Scholar
• FREEDMAN RR, NORTON D, WOODWARD S, CORNELISSEN G: Core body temperature and circadian rhythm of hot flashes in menopausal women. J Clin. Endocrinol Metab (1995) 80(8):2354–2358.
   PubMed Web of Science ®Google Scholar
• VERMEULEN A: Clinical review 24: androgens in the aging male. J Clin. Endocrinol Metab (1991) 73(2):221–224.
   PubMed Web of Science ®Google Scholar
• GRAY A, FELDMAN HA, MCKINLAY JB, LONGCOPE C: Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study./ Clin. Endocrinol Metab. (1991) 73(5):1016–1025.
   Google Scholar
• NAHOUL K, ROGER M: Age-related decline of plasma bioavailable testosterone in adult men. J. Steroid Biochem. (1990) 35(2):293–299.
   PubMedGoogle Scholar
• MATSUMOTO AM: Andropause: clinical implications of the decline in serum testosterone levels with aging in men. Gerontol A. Biol. Sci. Med. Sci. (2002) 57(2):M76–M99.
   Google Scholar
• ROSENBERG J, LARSEN SH: Hypothesis: pathogenesis of postmenopausal hot flash. Med. Hypotheses (1991) 35(4):349–350.
   PubMedGoogle Scholar
• KRONENBERG F, DOWNEY JA: Thermoregulatory physiology of menopausal hot flashes: a review. Can. J. Physiol Pharmacol (1987) 65(6):1312–1324.
   PubMedGoogle Scholar
• LOPRINZI CL, GOLDBERG RM, O'FALLON JR et al.: Transdermal clonidine for ameliorating post-orchiectomy hot flashes. J. Urol. (1994) 151(3):634–636.
   Google Scholar
• LOPRINZI CL, MICHALAK JC, QUELLA SK et al.: Megestrol acetate for the prevention of hot flashes. N Engl. J. Med. (1994) 331(0:347–352.
   PubMedGoogle Scholar
• LOPRINZI CL, SLOAN JA, PEREZ EA et al.: Phase III evaluation of fluoxetine for treatment of hot flashes. J. Clin. Oncol (2002) 20(6):1578–1583.
   PubMed Web of Science ®Google Scholar
• LOPRINZI CL, KUGLER JW, SLOAN JA et al.: Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet (2000) 356(9247):2059–63.
   PubMed Web of Science ®Google Scholar
• SLOAN JA, LOPRINZI CL, NOVOTNY PJ, BARTON DL, LAVASSEUR BI, WINDSCHITL H: Methodologic lessons learned from hot flash studies. J. Clin. Oncol (2001) 19(23):4280–4290.
   PubMed Web of Science ®Google Scholar
• CARPENTER JS, GILCHRIST JM, CHEN K, GAUTAM S, FREEDMAN RR: Hot flashes, core body temperature, and metabolic parameters in breast cancer survivors. Menopause (2004) 11(4):375–381.
   PubMed Web of Science ®Google Scholar
• BARTON DL, LOPRINZI CL, QUELLA SK et al.: Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J. Clin. Oncol (1998) 16(2):495–500.
   PubMed Web of Science ®Google Scholar
• LOBO RA, MCCORMICK W, SINGER F, ROY S: Depo- medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women. Obstet. GynecoL (1984) 63(1):1–5.
   PubMedGoogle Scholar
• NOTELOVITZ M, LENIHAN JP, MCDERMOTT M, KERBER IJ, NANAVATI N, ARCE J: Initial 17beta-estradiol dose for treating vasomotor symptoms. Obstet. GynecoL (2000) 95(5):726–731.
   PubMed Web of Science ®Google Scholar
• GARG PP, KERLIKOWSKE K, SUBAK L, GRADY D: Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet. GynecoL (1998) 92(3):472–479.
   PubMedGoogle Scholar
• COUGHLIN SS, GIUSTOZZI A, SMITH SJ, LEE NC: A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J. Clin. Epidemiol. (2000) 53(4):367–375.
   PubMedGoogle Scholar
• SMITH DC, PRENTICE R, THOMPSON DJ, HERRMANN WL: Association of exogenous estrogen and endometrial carcinoma. N Engl. J. Med. (1975) 293(23):1164–1167.
   PubMed Web of Science ®Google Scholar
• HOIBRAATEN E, QVIGSTAD E, ARNESEN H, LARSEN S, WICKSTROM E, SANDSET PM: Increased risk of recurrent venous thromboembolism during hormone replacement therapy-results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb. Haemost. (2000) 84(6):961–967.
   PubMedGoogle Scholar
• GRADY D, WENGER NK, HERRINGTON D: Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann. Intern. Med. (2000) 132(9):689–696.
   PubMed Web of Science ®Google Scholar
• HULLEY S, FURBERG C, BARRETT-CONNOR E: Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA (2002) 288(1):58–66.
   Google Scholar
• FURBERG CD, VITTINGHOFF E, DAVIDSON M et al.: Subgroup interactions in the Heart and Estrogen/ Progestin Replacement Study: lessons learned. Circulation (2002) 105(8):917–922.
   PubMedGoogle Scholar
• HULLEY SB, BITTNER V FURBERG C et al.: Hormone treatment-misconceptions and agreements. Eur. Heart J. (2002) 23(1):89–91.
   Google Scholar
• CHEN CL, WEISS NS, NEWCOMB P, BARLOW W, WHITE E: Hormone replacement therapy in relation to breast cancer. JAMA (2002) 287(0:734–741.
   PubMedGoogle Scholar
• VASTAG B: Hormone replacement therapy falls out of favor with expert committee. JAMA (2002) 287(15):1923–1924.
   PubMedGoogle Scholar
• VASSILOPOULOU-SELLIN R, ASMAR L, HORTOBAGYI GN et al.: Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. J. an. OncoL (1999) 17(5):1482–1487.
   PubMedGoogle Scholar
• COL NF, HIROTA LK, ORR RK, ERBAN JK, WONG JB, LAU J: Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J. Clin. OncoL (2001) 19(8):2357–2363.
   PubMed Web of Science ®Google Scholar
• ATALA A, AMIN M, HARTY JI: Diethylstilbestrol in treatment of postorchiectomy vasomotor symptoms and its relationship with serum follicle-stimulating hormone, luteinizing hormone, and testosterone. Urology (1992) 39(2):108–110.
   PubMedGoogle Scholar
• BERENDSEN HH: The role of serotonin in hot flushes. Maturitas (2000) 36(3):155–164.
   PubMed Web of Science ®Google Scholar
• GONZALES GF, CARRILLO C: Blood serotonin levels in postmenopausal women: effects of age and serum oestradiol levels. Maturitas (1993) 17(1):23–29.
   PubMedGoogle Scholar
• BLUM I, VERED Y, LIFSHITZ A et aL: The effect of estrogen replacement therapy on plasma serotonin and catecholamines of postmenopausal women. Isr. J. Med. Sci. (1996) 32(12):1158–1162.
   PubMedGoogle Scholar
• SUMMER BE, FINK G: Estrogen increases the density of 5-hydroxytryptamine(2A) receptors in cerebral cortex and nucleus accumbens in the female rat. J. Steroid Biochem. MoL Biol. (1995) 54(1-2):15–20.
   PubMedGoogle Scholar
• FINK G, SUMNER BE: Oestrogen and mental state. Nature (1996) 383(6598):306.
   PubMedGoogle Scholar
• GUDELSKY GA, KOENIG JI, MELTZER HY: Thermoregulatory responses to serotonin (5-HT) receptor stimulation in the rat. Evidence for opposing roles of 5-HT2 and 5-HT1A receptors. Neuropharmaco/ogy (1986) 25(12):1307–1313.
   Google Scholar
• MAZZOLA-POMIETTO P, AULAKH CS, WOZNIAK KM, HILL JL, MURPHY DL: Evidence that 142,5-dimethoxy-4-iodopheny1)-2-aminopropane (DOI)-induced hyperthermia in rats is mediated by stimulation of 5-HT2A receptors. Psychopharmacology (1995) 117(2):193–199.
   PubMed Web of Science ®Google Scholar
• BERENDSEN HH, BROEKKAMP CL: Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice. Br. J. PharmacoL (1990) 101(3):667–673.
   PubMedGoogle Scholar
• HARVEY AT, RUDOLPH RL, PRESKORN SH: Evidence of the dual mechanisms of action of venlafaxine. Arch. Gen. Psychiatry (2000) 57(5):503–509.
   PubMed Web of Science ®Google Scholar
• LOPRINZI CL, PISANSKY TM, FONSECA R et al.: Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors./ Clin. OncoL (1998) 16(7):2377–2381.
   Google Scholar
• QUELLA SK, LOPRINZI CL, SLOAN J et aL: Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J. UroL (1999) 162(1):98–102.
   PubMed Web of Science ®Google Scholar
• STEARNS V, ISAACS C, ROWLAND J et al.: A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann. OncoL (2000) 11(1):17–22.
   PubMed Web of Science ®Google Scholar
• WEITZNER MA, MONCELLO J, JACOBSEN PB, MINTON S: A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J. Pain Symptom Manage. (2002) 23(4):337–345.
   PubMed Web of Science ®Google Scholar
• LOPRINZI CL, BARTON DL, CARPENTER LA et al.: Pilot evaluation of paroxetine for treating hot flashes in men. Mayo Clin. Proc. (2004) 79(10):1247–1251.
   PubMed Web of Science ®Google Scholar
• STEARNS V BEEBE KL, IYENGAR M, DUBE E: Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA (2003) 289(21):2827–2834.
   PubMedGoogle Scholar
• STEARNS V, ISAACS C, HENRY-TILLMAN A et aL: Paroxetine is an effective therapy for hot flashes: results from a prospective randomized clinical trial. Proc. Am. Soc. Clin. OncoL (2003) 22:2940a.
   Google Scholar
• SUVANTO-LUUKKONEN E, KOIVUNEN R, SUNDSTROM H et aL: Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause (2005) 12(1):18–26.
   PubMed Web of Science ®Google Scholar
• BARTON DL, LOPRINZI CL, NOVOTNY P et al.: Pilot evaluation of citalopram for the relief of hot flashes. J. Support Oncol. (2003) 1(1):47–51.
   PubMedGoogle Scholar
• PEREZ DG, LOPRINZI CL, BARTON DL et al.: Pilot evaluation of mirtazapine for the treatment of hot flashes. J. Support OncoL (2004) 2:50–56.
   PubMedGoogle Scholar
• KIMMICK GG, LJ, MCQUELLON R, ROBINSON E, MUSS H: Randomized, placebo-controlled study of sertraline (Zoloft114) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Proc. Am. Soc. Clin. OncoL (2001) 20:1585a.
   Google Scholar
• ROTH AJ, SCHER HI: Sertraline relieves hot flashes secondary to medical castration as treatment of advanced prostate cancer. Psychooncology (1998) 7(2):129–132.
   PubMed Web of Science ®Google Scholar
• SPINA E, SCORDO MG, D'ARRIGO C: Metabolic drug interactions with new psychotropic agents. Funam. Clin. PharmacoL (2003) 17(5):517–538.
   PubMed Web of Science ®Google Scholar
• STEARNS V, JOHNSON MD, RAE JM et al.: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. j NatL Cancer Inst. (2003) 95(23):1758–1764.
   PubMed Web of Science ®Google Scholar
• JIN Y, DESTA Z, STEARNS Vet al.: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl .Cancer Inst. (2005) 97(1):30–39.
   Google Scholar
• JEFFERY SM, PEPE JJ, POPOVICH LM, VITAGLIANO G: Gabapentin for hot flashes in prostate cancer. Ann. Pharmacother. (2002) 36(3):433–436.
   PubMedGoogle Scholar
• GUTTUSO TJ Jr: Gabapentin's effects on hot flashes and hypothermia. Neurology (2000) 54(11):2161–2163.
   PubMedGoogle Scholar
• LOPRINZI L, BARTON DL, SLOAN JA et aL: Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin. Proc. (2002) 77(11):1159–1163.
   PubMed Web of Science ®Google Scholar
• THUMMALA AR, GRIGGS J, ROSENBLATT J et al.: Pilot study using gabapentin on tamoxifen-induced hot flashes in women with breast cancer. Proc. Am. Soc. Clin. OncoL (2002) 21:Abstract 1445
   Google Scholar
• GUTTUSO T Jr, KURLAN R, MCDERMOTT MP, KIEBURTZ K: Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet. GynecoL (2003) 101(2):337–345.
   PubMedGoogle Scholar
• PANDYA KJ, ROSCOE J, PAJON E et al.: A preliminary report of a double blind placebo controlled trial of gabapentin for control of hot flashes in women with breast cancer. A University of Rochester Cancer Center CCOP study. J. Clin. OncoL (2004) 22(145):8017a.
   Google Scholar
• PANDYA KJ, RAUBERTAS RF, FLYNN PJ et aL: Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clin. Oncol Program study. Ann. Intern. Med. (2000) 132(10):788–793.
   PubMed Web of Science ®Google Scholar
• GOLDBERG RM, LOPRINZI CL, O'FALLON JR et al.: Transdermal clonidine for ameliorating tamoxifen-induced hot flashes./ Clin. Oncol (1994) 12(1):155–158.
   Google Scholar
• DAVID A, DON R, TAJCHNER G, WEISSGLAS L: Veralipride: alternative antidopaminergic treatment for menopausal symptoms. Am. J. Obstet. Gynecol. (1988) 158(5):1107–1115.
   PubMedGoogle Scholar
• WESEL S, BOURGUIGNON RP, BOSUMA WB: Veralipride versus conjugated oestrogens: a double-blind study in the management of menopausal hot flushes. Curr. Med. Res. Opin. (1984) 8(10):696–700.
   PubMed Web of Science ®Google Scholar
• GOODWIN J, GREEN SJ, GIARRIRTA Set al.: Double blind Phase III trial of placebo (P) versus megestrol acetate (MA) 20 mg versus MA 40 mg as treatment for symptoms of ovarian failure in breast cancer survivors: initial results of Southwest Oncology Group S9626. San Antonio Breast Cancer Symposium. San Antonio, TX, USA (2001).
   Google Scholar
• QUELLA SK, LOPRINZI CL, SLOAN JA et al.: Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer (1998) 82(9):1784–1788.
   PubMed Web of Science ®Google Scholar
• BARTON D, LOPRINZI C, QUELLA S, SLOAN J, PRUTHI S, NOVOTNY P: Depomedroxyprogesterone acetate for hot flashes. J. Pain Symptom Manage. (2002) 24(6):603–607.
   PubMedGoogle Scholar
• SCHIFF I, TULCHINSKY D, CRAMER D, RYAN KJ: Oral medroxyprogesterone in the treatment of postmenopausal symptoms. JAMA (1980) 244(13):1443–1445.
   PubMed Web of Science ®Google Scholar
• DAWSON NA, MCLEOD DG: Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J. Urol. (1995) 153(6):1946–1947.
   PubMedGoogle Scholar
• WEHBE TW, STEIN BS, AKERLEY WL: Prostate-specific antigen response to withdrawal of megestrol acetate in a patient with hormone-refractory prostate cancer. Mayo Clin. Proc. (1997) 72(10):932–934.
   PubMedGoogle Scholar
• BURCH PA, LOPRINZI CL: Prostate-specific antigen decline after withdrawal of low-dose megestrol acetate. J. Clin. Oncol. (1999) 17(3):1087–1088.
   PubMedGoogle Scholar
• EATON AC, MCGUIRE N: Cyproterone acetate in treatment of post-orchidectomy hot flushes. Double-blind cross-over trial. Lancet (1983) 2(8363):1336–1337.
   PubMedGoogle Scholar
• QUELLA SK, LOPRINZI CL, BARTON DL et al.: Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J. Clin. Oncol (2000) 18(5):1068–1074.
   PubMed Web of Science ®Google Scholar
• VAN PATTEN CL, OLIVOTTO IA, CHAMBERS GK et al.: Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J. Clin. Oncol (2002) 20(0:1449–1455.
   PubMedGoogle Scholar
• VINCENT A, FITZPATRICK LA: Soy isoflavones: are they useful in menopause? Mayo Clin. Proc. (2000) 75(11):1174–1184.
   Google Scholar
• UPMALIS DH, LOBO R, BRADLEY L, WARREN M, CONE FL, LAMIA CA: Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Menopause (2000) 7(4):236–242.
   PubMed Web of Science ®Google Scholar
• VIGNA GB, PANSINI F, BONACCORSI G et al.: Plasma lipoproteins in soy-treated postmenopausal women: a double-blind, placebo-controlled trial. Num Metab Cardiovasc Dis (2000) 10(6):315–322.
   PubMedGoogle Scholar
• ALBERTAZZI P, PANSINI F, BOTTAZZI M, BONACCORSI G, DE ALOYSIO D, MORTON MS: Dietary soy supplementation and phytoestrogen levels. Obstet. Gynecol. (1999) 94(2):229–231.
   PubMedGoogle Scholar
• ALBERTAZZI P, PANSINI F, BONACCORSI G, ZANOTTI L, FORINT E, DE ALOYSIO D: The effect of dietary soy supplementation on hot flushes. Obstet. Gynecol. (1998) 91(1):6–11.
   PubMed Web of Science ®Google Scholar
• SCAMBIA G, MANGO D, SIGNORILE PG et al.: Clinical effects of a standardized soy extract in postmenopausal women: a pilot study. Menopause (2000) 7(2):105–111.
   PubMed Web of Science ®Google Scholar
• HAN KK, SOARES JM Jr, HAIDAR MA, DE LIMA GR, BARACAT EC: Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. Obstet. Gynecol. (2002) 99(3):389–394.
   PubMed Web of Science ®Google Scholar
• KRONENBERG F, FUGH-BERMAN A: Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann. Intern. Med. (2002) 137(14805–813.
   Google Scholar
• JACOBSON JS, TROXEL AB, EVANS Jet al.: Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J. Clin. Oncol. (2001) 19(10):2739–2745.
   Google Scholar
• BABER RJ, TEMPLEMAN C, MORTON T, KELLY GE, WEST L: Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women. Climacteric (1999) 2(2):85–92.
   PubMedGoogle Scholar
• KNIGHT DC, HOWES JB, EDEN JA: The effect of promensil, an isoflavone extract, on menopausal symptoms. Climacteric (1999) 2(2):79–84.
   PubMedGoogle Scholar
• HIRATA JD, SWIERSZ LM, ZELL B, SMALL R, ETTINGER B: Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil. Steril (1997) 68(0:981–986.
   PubMedGoogle Scholar
• WIKLUND IK, MATTSSON LA, LINDGREN R, LIMONI C: Effects of a standardized ginseng extract on quality of life and physiological parameters in symptomatic postmenopausal women: a double-blind, placebo-controlled trial. Swedish Alternative Medicine Group. Int. J. Clin. Pharmacol Res. (1999) 19(3):89–99.
   PubMedGoogle Scholar
• DAVIS SR, BRIGANTI EM, CHEN RQ, DALAIS FS, BAILEY M, BURGER HG: The effects of Chinese medicinal herbs on postmenopausal vasomotor symptoms of Australian women. A randomised controlled trial. Med. J. Aust. (2001) 174(2):68–71.
   Google Scholar
• WYON Y, WIJMA K, NEDSTRAND E, HAMMAR M: A comparison of acupuncture and oral estradiol treatment of vasomotor symptoms in postmenopausal women. Climacteric (2004) 7(2):153–164.
   PubMed Web of Science ®Google Scholar
• SANDBERG M, WIJMA K, WYON Y, NEDSTRAND E, HAIVIMAR M: Effects of electro-acupuncture on psychological distress in postmenopausal women. Complement Ther Med (2002) 10(10):161–169.
   PubMedGoogle Scholar
• WYON Y, LINDGREN R, HAMMAR M, LUNDEBERG T: Acupuncture against climacteric disorders? Lower number of symptoms after menopause. Lakartidningen (1994) 91:2318–2322
   PubMedGoogle Scholar
• HAIVIMAR M, FRISK J, GRIMAS O, HOOK M, SPETZ AC, WYON Y: Acupuncture treatment of vasomotor symptoms in men with prostatic carcinoma: a pilot study./ Urol. (1999) 161(3):853–856.
   PubMedGoogle Scholar